X-Zell logo

X-Zell

Early, pain-free cancer detection.

Winter 2015Healthcare / Healthcare -> DiagnosticsSingapore, Singapore; Bangkok, Thailand; Düsseldorf, NRW, Germany19 employees
Medical Devices

About

X-ZELL™ is a global start-up specialising in rare cell detection technology. Backed by Y Combinator and various high-profile angel investors from around the globe – among them Gmail creator Paul Buchheit – X-ZELL™ has developed a world-first platform technology capable of isolating and visualizing rare and abnormal cells such as Circulating Endothelial Cells (CEC). X-ZELL™’s platform technology is based on four core modules covering the entire spectrum from blood processing through to cell analysis and reporting – with every step performed in-house using patented and proprietary technology. By combining the wisdom of 4,000 years of pathologic research with X-ZELL™’s own, cutting-edge technology, X-ZELL™ ensures robust results and maximum clinical utility across a broad range of medical applications – from research through to medication management, companions diagnostics, relapse control and diagnostic decision-making. More information on www.x-zell.com and @XZELLInc

Build your own investing agent

GPAgent keeps YC listings public and neutral. Fund-specific scoring, notes, and workflow state live in each customer workspace.

Join the GPAgent waitlist

Founders (2)

Prapat Suriyaphol
Founder
Sebastian Punyaratabandhu Bhakdi
Founder

Details

Status
Active
Stage
Early
Team Size
19
Regions
Singapore, Thailand, Germany, Southeast Asia, Europe, Remote, Partly Remote